Anti-Müllerian hormone (AMH) levels in premenopausal breast cancer patients treated with taxane-based adjuvant chemotherapy – A translational research project of the SUCCESS A study

Trapp, Elisabeth; Steidl, Julia; Rack, Brigitte; Kupka, M.; Andergassen, Ulrich; Jückstöck, Julia; Kurt, A; Vilsmaier, Theresa�; Gregorio, Amelie de; Gregorio, Nikolaus de; Tzschaschel, M; Lato, Christiane; Polasik, A; Tesch, Hans; Schneeweiß, Andreas; Beckmann, Matthias W.; Fasching, Peter A.; Müller, Volkmar

doi:10.1016/j.breast.2017.07.007

Cited by 19 publications

(18 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We recruited all our patients from the SUCCESS-A trial 20 (EudraCT 2005-000490-21). The ethic committee of the Ludwig-Maximilians-University Munich approved the study.…”

Section: Methodsmentioning

confidence: 99%

VEGF-A165b levels are reduced in breast cancer patients at primary diagnosis but increase after completion of cancer treatment

Karsten

Beck

Rademacher

et al. 2020

Sci Rep

View full text Add to dashboard Cite

The antiangiogenic splice variant VEGF-A165b is downregulated in a variety of cancer entities, but little is known so far about circulating plasma levels. The present analysis addresses this question and examines circulating VEGF-A/VEGF-A165b levels in a collective of female high-risk breast cancer patients over the course of treatment. Within the SUCCES-A trial 205 patients were recruited after having received primary breast surgery. Using ELISA VEGF-A/VEGF-A165b concentrations were determined and correlated to clinical characteristics (1) before adjuvant chemotherapy, (2) four weeks and (3) two years after therapy and compared to healthy controls (n = 107). VEGF 165b levels were significantly elevated after completion of chemotherapy. Within the breast cancer cohort, VEGF-A165b levels increased two years after completion of chemotherapy. VEGF-A plasma concentrations were significantly elevated in the breast cancer cohort at all examined time points and decreased after treatment. VEGF-A levels two years after chemotherapy correlated with increased cancer related mortality, no such correlation could be found between VEGF-A165b and the examined clinical characteristics. Compared to controls, VEGF-A/ VEGF-A165b ratios were decreased in patients before and after chemotherapy. Our data suggests that circulating VEGF-A165b is significantly reduced in women with primary breast cancer at time of diagnosis; furthermore, levels change during adjuvant treatment. Already in the 19th century, the great pathologist Rudolf Virchow described the abundant vascularization found in many tumors 1. However, almost another century needed to pass until Senger discovered in 1983 a protein which led to a strong increase in the permeability of abdominal vasculature which he therefore named "vascular permeability factor" 2. In 1989 Ferrara and colleagues found a heparin binding growth factor that specifically activated vascular endothelial cells and coined the term vascular endothelial growth factor VEGF 3. Now we know that VEGF is not only one protein, but rather a family of growth factors with a similar protein structure but different abilities. Seven different human glycoproteins termed VEGF-A, VEGF-B, VEGF-C, VEGF-D, and placental like growth factor (PlGF) have been identified so far 4. VEGF-A is a family of different isoforms (VEGF-A121, VEGF-A165, VEGF-A183, VEGF-A189, VEGF-A206 and VEGF-A165b) with different functions and sizes. The coding gen for it lies on chromosome 6p21.3 5 and consists of eight exons and seven introns 6. Alternative splicing at exon six and seven as well as at the proximal end of exon 8a leads to a variety of proangiogenic isoforms of VEGF. In 2002 Bates et al. 7 were the first to describe a new splice variant that differed from the known ones in its biologic function. This splice variant named VEGF-A165b deviates from VEGF-A in six amino acids at the carboxy terminal 3′ end changing the exonic structure from CDKPRR to SLTRKD and from an angiogenic to

show abstract

“…We recruited all our patients from the SUCCESS-A trial 20 (EudraCT 2005-000490-21). The ethic committee of the Ludwig-Maximilians-University Munich approved the study.…”

Section: Methodsmentioning

confidence: 99%

VEGF-A165b levels are reduced in breast cancer patients at primary diagnosis but increase after completion of cancer treatment

Karsten

Beck

Rademacher

et al. 2020

Sci Rep

View full text Add to dashboard Cite

show abstract

“…In view of these findings, predictors that show which women have a particularly high risk of chemotherapy-induced premature ovarian insufficiency could be useful when deciding whether to administer additional treatment with a GnRH analogue. Potential predictors currently being discussed include anti-Müllerian hormone (AMH) 29 or genetic germline cell variants associated with age at menarche and menopause 30 , 31 , 32 , 33 .…”

Section: New Aspects Of Systemic Therapy For Primary Breast Cancermentioning

confidence: 99%

“…Es werden z. B. das Anti-Müller-Hormon (AMH) 29 oder genetische Keimbahnvarianten, die mit Beginn und Ende der Regelblutung zusammenhängen, als Prädiktoren diskutiert 30 , 31 , 32 , 33 .…”

Section: Gnrh Als Ovarieller Protektor Unter Chemotherapie Bestätigt unclassified

Update Breast Cancer 2018 (Part 1) – Primary Breast Cancer and Biomarkers

Taran

Schneeweiß

Lux

et al. 2018

Geburtshilfe Frauenheilkd

View full text Add to dashboard Cite

This summary provides an overview of how new therapies or new aspects of established therapies relate to the latest findings. Neoadjuvant therapy, local therapy, new aspects of systemic therapy, and prognostic and predictive factors are presented. In the neoadjuvant setting, the association between pathological complete response (pCR) and prognosis is still of interest as is the identification of new molecular predictors for new therapies such as CDK4/6 inhibitors. As regards surgical treatment, the target is still to reduce the aggressiveness of surgery. To achieve this, a better understanding particularly of ductal carcinoma in situ is required. With regard to systemic therapy, more data on the best combinations and therapy sequences for existing therapies is available. Finally, the use of prognostic and predictive factors may help to avoid overtreatment and ensure that patients only receive therapies which have been shown to be effective for their specific condition and have fewer side effects.

show abstract

“…Es werden z. B. das Anti-Müller-Hormon (AMH) [29] oder genetische Keimbahnvarianten, die mit Beginn und Ende der Regelblutung zusammenhängen, als Prädiktoren diskutiert [30 -33].…”

Section: Gnrh Als Ovarieller Protektor Unter Chemotherapie Bestätigtunclassified

Update Mammakarzinom 2018 (Teil 1) – primäres Mammakarzinom und Biomarker

Taran

Schneeweiß

Lux

et al. 2018

Senologie - Zeitschrift für Mammadiagnostik und -therapie

View full text Add to dashboard Cite

ZusammenfassungIn dieser Übersichtsarbeit wird dargestellt, wie neue Therapien oder neue Aspekte etablierter Therapien in Zusammenhang mit neuesten, aktuellen Erkenntnissen stehen. Neoadjuvanz, Lokaltherapie, neue Aspekte der Systemtherapie und Prognose- sowie Prädiktivfaktoren werden beleuchtet. In der Neoadjuvanz ist nach wie vor der Zusammenhang zwischen pCR und Prognose von Interesse, ebenso wie neue molekulare Prädiktoren für neue Therapien wie CDK4/6-Inhibitoren zu identifizieren. Bei der operativen Behandlung wird weiter nach einer Reduktion der Aggressivität gestrebt. Insbesondere das duktale Carcinoma in situ muss dafür noch besser verstanden werden. Bei den Systemtherapien wächst die Datenlage zum Verständnis der besten Kombinationen und Therapieabläufe für bestehende Therapieverfahren. Letztendlich muss mithilfe von Prognose- und Prädiktivfaktoren vermieden werden, dass Übertherapien stattfinden und nur die Patientin spezifische Therapien erhält, welche bei dieser individuellen Patientin eine nachgewiesene Wirksamkeit mit wenig Nebenwirkungen haben.

show abstract

Anti-Müllerian hormone (AMH) levels in premenopausal breast cancer patients treated with taxane-based adjuvant chemotherapy – A translational research project of the SUCCESS A study

Cited by 19 publications

References 28 publications

VEGF-A165b levels are reduced in breast cancer patients at primary diagnosis but increase after completion of cancer treatment

VEGF-A165b levels are reduced in breast cancer patients at primary diagnosis but increase after completion of cancer treatment

Update Breast Cancer 2018 (Part 1) – Primary Breast Cancer and Biomarkers

Update Mammakarzinom 2018 (Teil 1) – primäres Mammakarzinom und Biomarker

Contact Info

Product

Resources

About